PRINCETON, N.J. and SAN DIEGO, June 30 Tobira TherapeuticsInc., a clinical stage biotechnology company committed to the research andproduct discovery against life-threatening and life-altering infectiousdiseases, today announced the organization of the company's senior managementteam. Tobira Therapeutics has been led since its inception in 2006 by JamesSapirstein, RPh, MBA as Chief Executive Officer and President. Joining Jamesis Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer,Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and QualityAssurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing andControls. These additions continue to build the management team withworld-class pharmaceutical development experts. "With this senior managementteam Tobira Therapeutics has more than 130 years of combined pharmaceuticalexperience, with the majority focused in biotech companies or HIV compounds.We are perfectly positioned to bring novel molecules to market that will playan important role in the treatment of HIV infection".
Dr. Palleja is the Chief Medical Officer, responsible for the overallclinical development of the Tobira Therapeutics portfolio. Sandra joinedTobira from Shionogi USA, where she lead numerous clinical programs as VicePresident of Clinical Development in several therapeutic categories includingan HIV joint venture with GSK. Prior to her years at Shionogi, Sandra gainedadditional experience from both Triangle Pharmaceutics and Hoffman-LaRoche,where she helped develop a variety of antivirals for HIV and hepatitisincluding FTC, DAPD, ganciclovir, and saquinavir. Prior to her career inindustry, she was the Director of the Infectious Diseases Clinic at St.Vincent's Hospital and Medical Center of New York City during the mid to late90's. Prior to her years at St. Vincent's, Sandra was an Associate Professorof Medicine, served as the Primary Care Liason to the AIDS Team at the AlbertEinstein College of Medicine and Bronx Municipal Hospital Center. From1989-1993, she also served as Consultant to the AIDS Institute, NYSDOH and theFederally Funded Ryan White Title III Program. She earned her MD from BostonUniversity School of Medicine.
Ms. Shashlo joined Tobira from Incyte Corporation where she held a similarrole as the VP of Regulatory Affairs and Quality Assurance. Prior to Incyte,Angie spent several years working with start-up companies such as Genaera,Vitagen and Ligand in a variety of roles including Project Management.Angeline spent many years working for larger pharmaceutical companies such asWyeth and Upjohn during the first half of her 25-year career in positions ofincreasing responsibility. Angie received her Bachelor of Science in Pharmacyfrom the University of Michigan.
Dr. Rheingold brings over 29 years of experience in new product scale-up,formulation development and manufacturing to Tobira Therapeutics. Jay hassuccessfully brought over 25 products to market during his tenure at Lederle,Hoffman-LaRoche, Bristol-Myers Squibb and Organon pharmaceutical companies.He received his doctorate in Pharmaceutical Sciences from the University ofConnecticut. Jay joins Tobira from Barrier Therapeutics, where he held theposition of Vice-President.
About Tobira Therapeutics, Inc.
Tobira Therapeutics is a private biopharmaceutical company which isfocused on developing and commercializing innovative antiviral compounds totreat HIV disease. The company was founded in 2006 by Eckard Weber, MD, apartner at the venture capital firm Domain Associates, to develop noveltreatments for HIV disease. Tobira has assembled a highly experiencedmanagement team with decades of clinical and commercial development experiencespecifically in HIV/AIDS drug development.Contact: Tobira Therapeutics Inc. James Sapirstein CEO and President Tobira Therapeutics, Inc. [email protected]